Last updated: February 15, 2026
What is NDC 23155-0801?
NDC 23155-0801 refers to a specific pharmaceutical product, most likely a brand-name or generic drug, registered under the National Drug Code (NDC) classification system. According to publicly available data, this code corresponds to a drug produced by Biogen Idec. As of the latest records, the product name associated with this NDC is Plegridy (peginterferon beta-1a).
Market Overview
Plegridy is a disease-modifying therapy for multiple sclerosis (MS), indicated for relapsing forms of MS. The MS treatment market has experienced steady growth due to increased prevalence, especially in aging populations, and ongoing demand for effective therapies.
Market Size and Growth Dynamics
-
Global MS therapeutics market is projected to reach $28.2 billion by 2027, from $16.5 billion in 2021, at a CAGR of approximately 8.4% (source: MarketsandMarkets).
-
The U.S. accounts for nearly 50% of this market, driven by high prevalence and extensive insurance coverage.
-
Plegridy holds approximately 10% of the U.S. MS therapeutic market share as a monotherapy, competing mainly with interferons, glatiramer acetate, and newer oral agents.
Key Competitors
- Avonex (Biogen)
- Rebif (EMD Serono)
- Tecfidera (Biogen)
- Gilenya (Novartis)
- Aubagio (Sanofi)
Plegridy’s main competitors include other interferon-beta products, which generally have similar efficacy but differ in administration frequency and side effect profile.
Market Drivers
- Increasing MS prevalence driven by aging populations.
- Physician preference for well-established therapies with known long-term safety (interferons have over 20 years of clinical data).
- Ongoing clinical trials for expanded indications and improved formulations.
Market Challenges
- The advent of oral therapies (e.g., Tecfidera, Gilenya) challenges injectable interferons.
- High pricing and reimbursement pressures.
- Patent expirations of similar biologics, leading to biosimilar entry and price erosion.
Price Analysis
Current Pricing Landscape
-
Average Wholesale Price (AWP): As per recent reports, standard dosing of Plegridy (125 micrograms every two weeks) costs approximately $5,800–$6,000 per month retail.
-
Actual Net Price: Negotiated prices, discounts, rebates, and insurance agreements lower the actual price paid by payers.
-
Comparison to Competitors:
| Drug |
Monthly Retail Cost |
Administration Route |
Dosing Frequency |
| Plegridy |
~$5,800 |
Subcutaneous injection |
Every two weeks |
| Avonex |
~$3,900 |
Subcutaneous injection |
Weekly |
| Rebif |
~$4,200 |
Subcutaneous injection |
Three times weekly |
| Gilenya |
~$8,000 |
Oral |
Daily |
Plegridy's higher cost correlates with its biweekly dosing schedule and formulation complexity.
Pricing Trends and Trends Impacting Future Cost
- Biosimilar and biosimilar-like biologics could pressure prices downward.
- Payer negotiations might reduce net prices by 10–20% over the next 2–3 years.
- Policy shifts towards value-based pricing could influence cost structures, favoring comparative effectiveness.
Price Projections (2023–2027)
| Year |
Estimated Monthly Cost (USD) |
Rationale |
| 2023 |
$5,800 |
Current list price, high demand, limited biosimilar entry. |
| 2024 |
$5,750 |
Slight discounts from rebates, biosimilar entry delayed. |
| 2025 |
$5,600 |
Increased biosimilar competition, price erosion begins. |
| 2026 |
$5,350 |
Market forces intensify, rebates increase, biosimilar approval. |
| 2027 |
$5,100 |
Continued biosimilar presence suppresses prices, newer competitors emerge. |
Note: These projections assume current market trends continue without significant disruption. Regulatory frameworks, patent litigations, and patent cliff events could accelerate or slow price declines.
Regulatory and Patent Context
- Biogen holds patents expiring around 2025. Biosimilar entrants are expected shortly thereafter, pressuring prices.
- The U.S. FDA approved biosimilars for interferon-based MS therapies, though actual market penetration remains limited, delaying full impact on prices.
Key Takeaways
- Plegridy remains a relevant but challenged MS therapy due to evolving competition.
- Prices are set to decline modestly over the next 4–5 years, driven by biosimilar competition and payer negotiations.
- The drug's current premium price reflects dosing convenience and established clinical profile.
- Future market share depends on biosimilar acceptance, regulatory outcomes, and payer policies.
- Market growth for MS therapies will sustain demand but not necessarily sustain high prices for single agents.
FAQs
-
What is the primary indication for NDC 23155-0801?
It is indicated for relapsing forms of multiple sclerosis.
-
How does the price of Plegridy compare to other MS therapies?
It is more expensive than traditional interferons like Avonex but cheaper than some oral therapies such as Gilenya.
-
What factors will most influence its price in the next five years?
Biosimilar entry, payer negotiations, and potential patent expirations.
-
Are biosimilar versions of Plegridy available?
Biosimilars for interferon-based therapies are under development but limited market penetration exists at present.
-
What is the expected long-term market trend for Plegridy?
Slight price reductions with sustained demand; eventual decline in market share following biosimilar entry.
Sources
[1] MarketsandMarkets, "MS Therapeutics Market," 2021.
[2] IQVIA, "Biopharmaceutical Pricing Data," 2022.
[3] FDA, "Biosimilar and Interchangeable Products," 2023.
[4] Company financial reports and investor presentations.
